Development of an Ultra-SensitiveEnzyme Immunoassay for Insulin and Its Application to the Evaluation of Diabetic Risk by Analysis of Morning Urine by Seiichi Hashida et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Development of an Ultra-Sensitive 
Enzyme Immunoassay for Insulin 
and Its Application to the Evaluation  
of Diabetic Risk by Analysis of Morning Urine 
Seiichi Hashida1,2, Yusuke Miyzawa1,  
Yoshie Hirajima1, Asako Umehara2,3,  
Mayumi Yamamoto1 and Satoshi Numata4 
1Human Life Science, Tokushima Bunri University, 
2Life Style Diseases, Institute for Health Sciences, Tokushima Bunri University, 
3Dietetics and Nutrition, Takamatsu Red Cross Hospital, 
4Health Science, University of Kochi, 
Japan 
1. Introduction 
1.1 Principle of immunoassay for peptides 
Currently available enzyme immunoassay methods for peptides can be divided into two 
groups, homogeneous and heterogeneous methods. Homogeneous enzyme immunoassay 
methods, in which signals that are directly obtained from a mixture of test samples and 
reagents correlate with the amount of peptide in test samples, are simpler and quicker but 
less sensitive than heterogeneous enzyme immunoassay methods, in which free and bound 
forms of enzyme-labeled reactants are separated from each other. 
Heterogeneous enzyme immunoassay methods can be divided into competitive and 
noncompetitive methods. In a typical competitive enzyme immunoassay method, a fixed 
amount of labeled peptide is reacted with the corresponding antibody in the absence and 
presence of the unlabeled peptide whose level is to be measured. The amount of the peptide 
to be measured correlates with the amount of labeled peptide that is bound to the antibody, 
which can only be measured within a certain range of error (approx. 5%). Assay sensitivity 
increases as the concentration of labeled peptide and antibody are decreased. However, the 
concentration of labeled peptide and antibody should be high enough so that more than 
50% of the labeled peptides and antibody used are in bound form. In other words, the 
minimum concentration of labeled peptide that can be used is limited by the affinity of the 
antibody. The sensitivity of a competitive enzyme immunoassay that is modified using a 
labeled antibody is also limited in a similar manner. In this type of assay, it makes no 
difference whether radioisotopes or enzymes are used as labels. In most cases the detection 
limit for peptides using such a modified competitive enzyme immunoassay is at femtomole 
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(10-15 moles) or higher levels. [Aikawa, 1979; Fyhrquist, 1976; Glänzer, 1984; Morton, 1975; 
Mukoyama, 1988; Scharpé, 1987; Tikkanen, 1985; Uno, 1985] 
In contrast to competitive assay methods, in noncompetitive immunoassay methods, the 
excess of enzyme-labeled antibody is efficiently eliminated by simple washing, and the 
amount of enzyme-labeled antibody nonspecifically bound to an antibody-coated solid 
phase in the absence of the antigen to be measured (background noise) can be minimized. 
This reduction in background noise makes it possible to achieve attomole sensitivities, 
provided that antibodies with sufficiently high affinity are used. Indeed, the reported 
detection limit for peptides, using noncompetitive enzyme immunoassay methods with 
appropriate techniques, is at attomole (10-18 moles) levels, as described below [Hashida, 
1991 & 1993; Ishikawa, 1983a & 1989]. 
Twenty years ago, a novel method (immune complex transfer method) was developed to 
lower the nonspecific binding of enzyme-labeled antibody without reducing the size of the 
solid phase surface or the reaction mixture volume used for immunoreactions [Hashida, 
1988]. For this method, the antigen to be measured was reacted simultaneously with a 2,4-
dinitrophenylated IgG antibody and a Fab' antibody that was labeled with -D-
galactosidase from Escherichia coli. The resulting immune complex, which was comprised 
of all three components, was trapped on polystyrene beads that were coated with affinity-
purified anti-2,4-dinitrophenyl group IgG. These polystyrene beads were then washed to 
eliminate the excess Fab'--D-galactosidase conjugate. The immune complex was eluted 
from the polystyrene beads with an excess of N-2,4-dinitrophenyl-L-lysine and was 
transferred to polystyrene beads coated with anti-IgG Fc portion IgG. This transfer resulted 
in more complete elimination of the Fab'--D-galactosidase conjugate that was 
nonspecifically bound to the polystyrene beads coated with the affinity-purified (anti-
dinitrophenyl group) IgG, thereby markedly reducing the background noise of the two-site 
enzyme immunoassay. Since there was also a smaller decrease in specific binding than in 
previous types of assays, these two features of the assay significantly improved assay 
sensitivity. Using this two-site immune complex transfer enzyme immunoassay, the 
detection limit of human ferritin was 1 zmol (zeptomole; 1  10-21 moles) per assay [Hashida, 
1990 & 1995]. 
1.2 Ultra-sensitive assay for insulin 
Insulin levels have typically been measured in serum using ELISA, which is a 
noncompetitive assay method [Lindström, 2002]. In order to determine insulin secretion 
ability, an oral glucose tolerance test (OGTT) is performed for which blood samples have to 
be collected every 30 min for 2 h. However, blood sampling involves risks of pain and 
infection. In contrast, urine samples can be collected more easily than serum samples. The 
insulin level in urine, collected at a specific time after serum insulin changes, may reflect 
these serum insulin levels. Thus urinary insulin levels may provide useful information 
regarding insulin secretion.  
In order to overcome the problem that urinary insulin levels are too low to be measured by 
conventional ELISA, we developed an ultra-sensitive immune complex enzyme 
immunoassay (ICT-EIA) to measure urinary insulin.  
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2. Materials and methods 
2.1 Buffers 
The following buffers were used. Buffer A: 10 mM sodium phosphate buffer (pH 7.0) 
containing 0.1 M NaCl, 1.0 g/l bovine serum albumin (BSA), 1.0 mM MgCl2 and 1.0 g/l 
NaN3; buffer B: 10 mM sodium phosphate buffer (pH 7.0) containing 0.4 M NaCl, 0.1 g/l 
BSA, 1 mM MgCl2 and 1.0 g/l NaN3. Bovine serum albumin (BSA; fraction V) was obtained 
from Intergen Co. (Purchase, NY). 
2.2 Human insulin, antibodies and ELISA 
Recombinant human insulin was purchased from Millipore (St. Charles, MO). Human 
resistin and human Insulin-like growth factors-I (IGF-I) were purchased from R&D Systems, 
Inc. (Minneapolis, MN). Human chorionic gonadotropin (hCG) was purchased from Roche 
Diagnostics K.K. (Tokyo, Japan). Human growth hormone (hGH) was purchased from JCR 
Pharmaceuticals Co., Ltd (Hyogo, Japan) 
Mouse anti-human insulin monoclonal antibodies (Ab-1; 16E9 and Ab-2; 6F7) were purchased 
from Japan Clinical Laboratories, Inc. (Nagoya, Japan). Guinea Pig anti-human insulin (Ab-3; 
N2PP05) antibody was purchased from Meridian Life Sci., Inc. (Saco, ME). Mouse anti-human 
resistin monoclonal antibodies (184305 and 184320) were purchased from R&D Systems. 
Rabbit (anti-2,4-dinitrophenyl (DNP)-BSA) serum was purchased from Shibayagi Co., Ltd. 
(Gunma, Japan). Rabbit anti-mouse Fc IgG was purchased from Thermo Sci. (Rockford, IL). 
The ELISA for insulin was purchased from Mercodia (Uppsala, Sweden). 
2.3 Subjects 
A total of 141 Japanese non-diabetic, non-obese (NDNO) and non-diabetic obese (NDO) 
volunteers and 42 Japanese diabetic patients (DM) from our clinic participated in the study 
(Table 1). Criteria for obese subjects in this study included: body mass index (BMI) of >25 
kg/m2 or percentage body fat ratio of >25% for men and >30% for women. The study 
protocol was approved by the ethics committees of Tokushima Bunri University and 
Tokushima University and all participants gave written informed consent. 
 
Parameters measured NDNO NDO DM 
              (mean ± SD) 
No. of subjects (male/female) 106 (10/96) 35 (12/23) 42 (27/15) 
Age (years) 30.3 ± 18.1 48.4 ± 7.0a 55.2 ± 27.7a,b 
BMI (kg/m2) 21.9 ± 2.9 27.0 ± 4.1a 25.1 ± 3.3a 
Fasting plasma glucose (mg/dl) 80.0 ± 12.7 84.5 ± 9.4a 119.6 ± 25.5a,b 
HbA1c (%) 4.8 ± 0.4 5.1 ± 0.3a 7.2 ± 1.5a,b 
aP < 0.01, compared with NDNO; bP < 0.01, compared with NDO. 
NDNO, non-diabetic, non-obese volunteers; NDO, non-diabetic obese volunteers; DM, diabetic patients 
Table 1. Clinical characteristics of the study groups 
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2.4 Blood and urine sampling 
Blood samples were drawn early in the morning from an antecubital vein of subjects who 
had fasted overnight. Samples were then transferred into chilled glass tubes and kept on ice 
for 30 min. Serum was separated from the samples by centrifugation at 1,500 x g for 15 min 
at 4 °C and kept frozen at -30 °C until analysis. 
Urine samples were collected early in the morning from non-diabetic and diabetic subjects 
who had fasted for 16 h. The urine samples (10 ml) were mixed with 0.1 ml of both BSA (100 
g/l) and NaN3 (100 g/l) and were kept frozen at -30 °C until analysis. Urinary albumin and 
creatinine were also measured using standard methods. Urine samples with micro- and 
macro-albuminuria were excluded. Urinary insulin levels were expressed as a ratio to the 
concentration (mg) of urinary creatinine (Cre). 
2.5 Antibody preparation 
IgG was prepared from serum by fractionation with Na2SO4 followed by passage through a 
column of diethylaminoethyl cellulose. Both polyclonal rabbit and monoclonal mouse IgGs 
were digested with pepsin to F(ab’)2, which was further reduced to obtain Fab’ [Hashida, 
1995]. 
2.6 Preparation of capture antibody and enzyme-labeled antibody 
Mouse anti-insulin Fab’ monoclonal antibody (Ab-1), guinea pig anti-insulin Fab’ polyclonal 
antibody (Ab-3) and mouse anti-human resistin monoclonal antibodies (184305) were each 
conjugated with 6-maleimidohexanoyl-DNP-biotinyl-BSA and used as a capture antibody 
[Hashida, 1995; Ishikawa, 1983b]. Mouse anti-insulin Fab’ monoclonal antibody (Ab-2) and 
mouse anti-human resistin monoclonal antibodies (184320) were conjugated with -D-
galactosidase from Escherichia coli using o-phenylenedimaleimide, or with horseradish 
peroxidase or alkaline phosphatase from calf intestine, using N-succinimidyl-6-
maleimidehexanoate and was used as an enzyme-labeled antibody [Hashida, 1995; 
Ishikawa, 1983b].  
Thiol groups were introduced into mouse anti-insulin IgG monoclonal antibody (Ab-4) 
using S-acetylmercaptosuccinic anhydride (Nacalai Tesque, Inc., Kyoto, Japan) and the 
antibody was then conjugated with 6-maleimidohexanoyl-DNP and 6-maleimidohexanoyl-
biocytin and used as a capture antibody [Hashida, 1995; Ishikawa, 1983b]. 
2.7 Preparation of protein-coated polystyrene beads 
Polystyrene beads (3.2-mm diameter; Immuno Chemical, Inc., Okayama, Japan) were coated 
with affinity-purified anti-DNP-BSA IgG (0.01 g/l), anti-mouse Fc IgG or biotinyl-BSA (0.01 
g/l) by physical adsorption [Hashida, 1995; Ishikawa, 1983b]. Biotinyl-BSA-coated polystyrene 
beads were then reacted with streptavidin (0.01 g/l) [Hashida, 1995; Ishikawa, 1983b]. 
2.8 Immunoenzymometric assay (IEMA) for insulin 
The protocol of the IEMA for insulin was as follows (Fig. 1): An aliquot (100 l) of standard 
human insulin, or urine sample, was incubated overnight at 4 °C with 100 l buffer B 
containing 100 fmol Ab-1 Fab’ conjugated with DNP-biotinyl-BSA and 30 fmol Ab-2 Fab’--
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D-galactosidase conjugate (Complex formation). Thereafter, one streptavidin-coated 
polystyrene bead was added and incubated for 30 min. The bead was then washed, and the 
bound -D-galactosidase activity was assayed fluorometrically with 4-methylumbelliferyl--
D-galactoside (0.2 mM) as the substrate for 1 h at 30 °C [Ishikawa, 1983b]. 
2.9 Two-site immune complex transfer enzyme immunoassay (ICT-EIA) for insulin 
The protocol of the ICT-EIA for insulin was as follows (Fig. 1): An aliquot (100 l) of standard 
human insulin diluted in buffer B, or urine sample, was incubated overnight at 4 °C with 100 
l buffer B containing 100 fmol of capture antibody conjugate; Ab-1 or Ab-3 Fab’ conjugated  
 
The ICT-EIA assay entails five steps: 1. Complex formation, during which the three assay components 
of capture antibody, antigen, and enzyme-conjugated antibody form a complex; 2. Entrapment, during 
which the formed complex is trapped on an anti-DNP solid phase; 3. Elution, during which the bound 
immune complex is eluted with DNP-Lysine solution; 4. Transfer, during which the eluted immune 
complex is transferred onto a streptavidin solid phase; 5. Enzyme assay, during which the activity of the 
enzyme bound to the immune complex is assayed fluorescently. The IEMA assay is outlined at the left 
for comparison. 
Ab, antibody; Ag, antigen; Lys, lysine.  
Color key: Blue 
Fig. 1. Schematic outline of the IEMA and ICT-EIA for insulin 
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with DNP-biotinyl-BSA or a DNP-biotinyl-Ab-1 IgG conjugate, and 30 fmol Ab-2 Fab’--D-
galactosidase conjugate (Complex formation). Thereafter, one polystyrene bead coated with 
affinity-purified IgG (anti-DNP-BSA) was added to the mixture and incubated for 30 min 
(Entrapment). After removal of the incubation mixture, the polystyrene bead was washed 
twice with buffer A and then incubated in 150 l buffer A containing 2 mM eN-2,4-DNP-L-
lysine for 30 min (Elution). After removal of the polystyrene bead, one streptavidin-coated 
polystyrene bead was added to the eluate and incubated for 30 min (Transfer). The bead was 
then washed, and the bound -D-galactosidase activity was assayed fluorometrically with 4-
methylumbelliferyl--D-galactoside (0.2 mM) as a substrate for 20 h at 30 °C [Hashida, 1995; 
Ishikawa, 1983b]. All incubations with polystyrene beads were performed with shaking at 210 
strokes/min at room temperature [Hashida, 1995; Ishikawa, 1983b]. 
To compare the assay of urinary insulin with assay of other urinary hormones derived from 
serum, ICT-EIAs for resistin were performed using a similar method as that described above 
for the ICT-EIA for insulin, including similar volumes of standard and samples, 
concentration of antibody conjugates, buffer, temperature and incubation times, except that, 
in the ICT-EIA for resistin, both DNP-biotinyl-BSA anti-resistin Fab’ (184305) and anti-
resistin Fab’(184320)-┚-D-galactosidase antibody conjugates were used.  
2.10 Measurement of urinary albumin and creatinine levels 
Albumin and creatinine levels were measured in first morning urine samples. Albumin 
levels were assessed with an ICT-EIA as described above but using a specific anti-albumin 
monoclonal antibody as described in previous report [Umehara, 2009] and creatinine levels 
were assessed by reaction with picric acid using a commercial kit (Creatinine-test Wako, 
Wako Pure Chemical Industries, Ltd., Osaka, Japan). 
2.11 Laboratory tests 
Plasma lipoproteins, total cholesterol, high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), triglycerides (TG) and HbA1c levels were analyzed consecutively using 
standard laboratory techniques by Bio Medical Laboratories, Inc. (Tokyo, Japan). 
2.12 OGTT test 
Eleven healthy young subjects (3 males and 8 females) ingested 75 g glucose. Blood samples 
were then obtained at 0, 60 and 120 min and urine samples at 0 and 120 min following 
ingestion. The levels of blood glucose and insulin, as well as levels of urinary insulin, were 
measured. 
2.13 Statistical analysis 
All data are presented as means ± SD. The detection limit of ICT-EIA or ELISA for insulin 
was expressed as the minimal amount of insulin which gives a significant bound enzyme 
activity (fluorescence or absorbance signal) after subtraction of the background signal (no 
insulin). A significant difference from the background was confirmed using Student’s t-test 
(P < 0.001, n = 5). 
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Statistical analysis was performed using SPSS version 20.0.0. Correlations were performed 
using Spearman’s correlation coefficient. Differences between two and three groups were 
compared using the Mann-Whitney U test and the Kruskal-Wallis test, respectively. 
3. Results 
3.1 IEMA for insulin 
To compare the newly developed ICT-EIA with other methods of insulin assay we performed 
an IEMA for insulin as outlined in Fig. 1. Insulin was simultaneously incubated with a mixture 
of a monoclonal (Mc) Ab-1 Fab’ conjugated with DNP-biotinyl-BSA (Mc-DNP) and a 
monoclonal (Mc) Ab-2 Fab’--D-galactosidase conjugate (Mc-Gal), resulting in the formation of 
an immune complex consisting of all three components. This immune complex was then 
trapped onto a streptavidin-coated solid phase. The solid phase was washed to eliminate 
unbound conjugates and the bound -D-galactosidase activity was measured fluorometrically. 
Using this assay the detection limit for insulin was 0.01 µU, which was 3-fold lower than 
that of a conventional ELISA (Fig. 2). 
 
The open symbols indicate the specifically bound peroxidase activity in the conventional ELISA. The 
closed symbols indicate the specifically bound -D-galactosidase activity in the IEMA performed using 
monoclonal capture and enzyme-conjugated antibodies  
Fig. 2. Calibration curves for insulin assay using IEMA and ELISA. 
3.2 ICT-EIA for insulin 
The ICT-EIA for insulin was performed as outlined in Figure 1. Insulin was simultaneously 
incubated with a mixture of Mc-DNP and Mc-Gal, to form an immune complex as described 
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for the IEMA method. This immune complex was first trapped onto a solid phase coated 
with anti-DNP IgG. Subsequently, the solid phase was washed to eliminate unbound 
conjugates and the immune complex was then specifically eluted from this solid phase using 
DNP-Lys and transferred onto a second solid phase coated with streptavidin. Finally, the 
bound -D-galactosidase activity was measured fluorometrically. 
When the same two mouse monoclonal antibodies that were used for IEMA were used for 
ICT-EIA, the fluorescence signal from the bound -D-galactosidase activity in the ICT-EIA 
was strongly decreased compared to that obtained in the IEMA at low insulin 
concentrations and was not linear with the lowest insulin concentrations. This effect resulted 
in a detection limit for insulin of 0.03 µU, which was 3-fold higher than that of the IEMA 
(Fig. 3). Similar results were obtained even if the high molecular weight -D-galactosidase 
(540 kDa) enzyme with which the antibody was conjugated was exchanged for a lower 
molecular weight enzyme such as peroxidase (40 kDa) or alkaline phosphatase (120 kDa) 
(data not shown). 
 
The closed symbols indicate the specifically bound -D-galactosidase activity in the IEMA as described 
in Fig. 1 using monoclonal capture (Mc-DNP) and enzyme-conjugated (Mc-Gal) antibodies respectively. 
The open symbols indicate the specifically bound -D-galactosidase activity in the ICT-EIA using the 
same two monoclonal antibodies that were used for IEMA.  
Fig. 3. Calibration curves for insulin assay using IEMA and ICT-EIA. 
We next tested the effect of using a combination of an enzyme labeled monoclonal mouse 
antibody (Mc-Gal) and a non-affinity purified polyclonal capture antibody (Pc-DNP) for 
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formation of the immune complex in ICT-EIA (Mc-Gal & Pc-DNP). The resulting 
fluorescence signal decreased linearly in accordance with insulin dilution. The detection 
limit for insulin was 0.0003 µU (12 fg; 1.8 amol) (Fig. 4), which was 30-fold lower than that of 
IEMA. When a polyclonal antibody was used for enzyme labeling and a monoclonal 
antibody for capture (Pc-Gal & Pc-DNP), or when both antibodies were the same polyclonal 
antibody, the insulin detection limit increased, but the linearity with insulin dilution was 
preserved (Fig. 5). 
 
The open symbols indicate the specifically bound -D-galactosidase activity in the ICT-EIA performed 
as described in Fig. 3. The closed symbols indicate the specifically bound -D-galactosidase activity in 
the ICT-EIA in which a combination of a polyclonal capture antibody (Pc-DNP) and a monoclonal 
enzyme-labeled antibody (Mc-Gal) was used. 
Fig. 4. Calibration curves for insulin assay using two different ICT-EIAs. 
3.3 Improved ICT-EIA for insulin and limit of urinary insulin detection 
Figure 5 shows typical calibration curves of the ICT-EIAs for insulin using various 
combinations of polyclonal/monoclonal capture and enzyme-conjugated antibodies. The 
detection limit and sensitivity for insulin using a polyclonal capture antibody and a 
monoclonal enzyme labeled antibody (Pc-DNP & Mc-Gal) was 0.0003 µU (0.3 nU) and 0.15 
µU/ml of urine, respectively, using 2-µl samples for complete recovery of the added insulin. 
This detection limit was 100-fold lower than that of a sensitive ELISA and of IEMA using 
Mc-DNP & Mc-Gal (Fig.2 and 3). The assay range (CV < 10) for insulin in urine was 0.5-
150 µU/ml, using urine samples with a volume of 2 µl. Based on these data the ICT-EIA 
using a polyclonal capture antibody and a monoclonal enzyme labeled antibody was used 
for the remainder of the study.  
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The closed squares indicate the specifically bound -D-galactosidase activity in the ICT-EIA in which a 
polyclonal capture antibody (Pc-DNP) and a monoclonal enzyme-labeled antibody (Mc-Gal) were used as 
described in Fig. 4. The open triangles indicate the specifically bound -D-galactosidase activity in an ICT-
EIA in which the polyclonal (Pc-Gal)/monoclonal antibody (Mc-DNP)  combination was reversed. The 
closed triangles indicate the specifically bound -D-galactosidase activity in an ICT-EIA in which the same 
polyclonal antibody was used for the capture and enzyme-labeled antibody (Pc-DNP & Pc-Gal). 
Fig. 5. Calibration curves for insulin assay using three different ICT-EIAs. 
3.4 Assay precision 
The reproducibility of ICT-EIA for analysis of insulin in urine was estimated using two or 
three samples containing different concentrations of insulin (range, 0.5-22.5 µU/ml). The 
within-assay and between-assay CVs for insulin were 2.5-6.2 (n = 10) and 3.5-7.5 (n = 10), 
respectively. 
3.5 Recovery and dilution tests 
Analytical recovery of exogenously added insulin to 2-µl and 5-µl urine samples (range, 1.2-
25.3 µU/ml) was 92.8-106 and 72.5-103, respectively. Dilution curves for the urine 
samples paralleled those for standard insulin. Based on these data, 2 µl of urine was used for 
all experiments described below. 
3.6 Specificity of ICT-EIA 
The cross-reactivity of ICT-EIA for insulin and other hormones was evaluated. In the ICT-
EIA for insulin, cross-reactions on a molar basis with hIGF-I, hCG and hGH were all <0.1%, 
indicating that ICT-EIA can specifically measure insulin concentrations.  
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3.7 Comparison with ELISA 
Insulin levels measured in 35 serum samples (3.3-23.1 µU/ml) using ICT-EIA correlated well 
with those determined by ELISA (r = 0.924, P < 0.001) (Fig. 6). 
 
The regression equation and the calculated correlation coefficient (n = 35, r = 0.924, P < 0.001) are 
shown. 
Fig. 6. Correlation between serum insulin levels measured by ELISA and by ICT-EIA. 
3.8 Effects of increased blood glucose levels after OGTT on the insulin concentration 
in serum and urine 
In order to determine whether the urinary insulin level reflects the blood insulin level, 
insulin levels in both serum and urine from non-diabetic healthy subjects were measured 
after OGTT using the ICT-EIA. Blood was collected at 0, 0.5, 1.0, 1.5 and 2.0 h, and urine was 
collected at 0 and 2 h after glucose ingestion. Blood glucose, serum insulin and insulin in the 
urine were measured (Table 2). Increases in the blood glucose level corresponded to 
significant increases in the blood insulin level, which were followed by increases in the 
urinary insulin level two hours later. The total quantity of insulin in urine was calculated 
based on the urine volume. A strong correlation was found between serum insulin levels at 
60 min after glucose ingestion and total insulin values in urine during 2 h after ingestion (r = 
0.87, P < 0.001), suggesting that measurement of insulin in urine may be useful for assessing 
the relative insulin levels in serum (Fig. 7). 
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Blood was collected at 1 h, and urine was collected at 0 and 2 h, after glucose ingestion. The regression 
equation and the calculated correlation coefficient (n = 23, r = 0.868, P < 0.001) are shown. 
Fig. 7. Correlation between serum and urinary insulin levels after OGTT. 
 
Serum and urine levels               Time after OGTT (h) 
 0 1 2 
Blood glucose (mg/dl) 82 ± 11 135 ± 29* 118 ± 18* 
Serum insulin (µU/ml) 3.1 ± 1.7 33.3 ± 25.9* 39.1 ± 45.0* 
Urine insulin (µU/mg creatinine) 3.0 ± 1.9        - 15.2 ± 8.1* 
*P < 0.01, compared with that at 0 h. 
Urine: 0 h, before OGTT; 2 h, during 2 h after the OGTT.  
Table 2. Concentration of glucose and insulin in serum, and of insulin in urine, in the oral 
glucose tolerance test (OGTT). 
3.9 Measurement of insulin and resistin concentrations in urine 
Urine samples were collected in the early morning from fasting NDNO and NDO subjects, 
and from fasting DM patients. Urinary insulin was measured by ICT-EIA and expressed in 
terms of µU/mg creatinine. The insulin concentrations determined in urine from NDNO 
and NDO subjects and from DM patients were 4.3 ± 2.8, 9.0± 5.5 and 13.9 ± 17.6 U/mg 
creatinine, respectively (Fig. 8); the insulin concentration was significantly higher in DM 
patients than in NDNO subjects (P < 0.001). 
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Urinary insulin levels are expressed as a boxplot (box-and-whisker diagram); scale bars indicate sample 
minimum and maximum, boxes indicate lower quartile, median and upper quartile. DNO (n = 106), 
NDO (n = 35) and DM (n = 42). Insulin levels are expressed relative to urinary creatinine (Cre).  
Fig. 8. Insulin levels in the urine of NDNO subjects, NDO subjects and DM patients. 
Resistin concentrations were also measured in urine from NDNO and NDO subjects and 
from DM patients and were determined to be 18.6 ± 20.9, 15.4 ± 17.2 and 30.0 ± 36.2 ng/mg 
creatinine, respectively (Fig. 9); the resistin concentration in DM subjects was significantly 
higher than in NDO and NDNO subjects (P < 0.05) (Fig. 9). 
 
Urinary resistin levels are expressed as a boxplot similar to that described in Fig. 8. 
Fig. 9. Resistin levels in the urine of NDNO and NDO subjects and of DM patients. 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 
 
96
3.10 Correlation of insulin level to resistin levels in urine 
We analyzed the correlation of urinary insulin level to urinary resistin level in 42 DM 
patients. The urinary insulin level was significantly and positively correlated to urinary 
levels of resistin (r = 0.426, P < 0.001) (Fig. 10). 
4. Discussion 
We developed a new ultra-sensitive technique for the measurement of insulin by employing 
a non-competitive two-site binding method that utilizes two different types of anti-insulin 
antibodies and an immune-complex transfer method (ICT-EIA). This new method can 
measure insulin levels as low as 0.3 nU (12 fg; 1.8 amol), with a sensitivity of 0.15 µU/ml, 
using 2-µl urine samples. This assay is 100-fold more sensitive than a sensitive ELISA. 
Various kinds of peptides can be measured at attomole levels by a non-competitive two-site 
enzyme immunoassay (ICT-EIA). For this purpose, the peptide molecules to be measured 
have to have two or more epitopes that are sufficiently separated from each other to allow 
simultaneous binding of two antibody molecules. A previous study using a single chain 
peptide provided a hint as to the distance required between epitopes for simultaneous 
binding of two antibodies. Human ┙-atrial natriuretic peptide (┙-hANP) is a single chain 
polypeptide consisting of 28 amino acids with a ring structure that is formed by an 
intramolecular disulfide bound [Hashida, 1988b]. Ten amol of ┙-hANP were measured by a 
two-site enzyme immunoassay using a peroxidase-labeled antibody Fab’ against the C-
terminus of the peptide and a solid phase coated with IgG against the N-terminal half of the 
ring structure. The distance between the two epitopes recognized by the two antibody 
molecules in this single chain peptide appeared to correspond to 12-15 amino acids. 
Since most polyclonal antibodies used in assays are now being replaced with monoclonal 
antibodies, a non-competitive two-site binding assay using two kinds of monoclonal 
antibody has recently been developed. When two kinds of monoclonal antibody were used 
in the ICT-EIA method, it was possible to measure most proteins at concentrations of less 
than attomole levels [Hashida, 1988b, 1990 & 1995]. 
However, it has not been possible to measure peptides, insulin, CRH, -ANP, 
adrenomedullin or PAMP at less than attomole levels with an ultra-sensitive assay (ICT-
EIA) using two monoclonal antibodies [Hashida, 2004; Katakami, 2002; Yamaga, 2003]. The 
major reason for this failure appeared to be due more to a decreased signal rather than 
because of dilution degree. Two factors have been considered that might contribute to this 
phenomenon. One factor is insufficient antibody affinity and the other is steric hindrance 
within an immune complex consisting of two antibodies (each of 50 kDa) and a peptide (6 
kDa). Both of these factors would contribute to weak binding of the antibodies to the 
peptide in the immune complex resulting in dissociation of the peptide from antibody 
during the transfer from the first to the second solid phase. 
We tested a number of combinations of ten different monoclonal anti-insulin antibodies, 
which varied in affinity and epitope, in the development of the ICT-EIA for insulin, but the 
results of all of the assays were the same (data not shown). We further examined the study 
due to the multi-antibody which several kinds of different  monoclonal antibodies to insulin 
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were caused by, but the results of these assays were again the same (data not shown). When 
the same polyclonal antibody, which was not insulin affinity-purified, was used as both the 
capture and the enzyme labeled antibody for ICT-EIA, a linear standard curve in accordance 
with insulin dilution was obtained, but the assay was of lower sensitivity than the other 
ICT-EIA assays (Fig. 5). Subsequently, a combination of one monoclonal and one non-
affinity purified polyclonal antibody to insulin was used and, in this assay, the detection 
limit of insulin was 1.8 amol and a linear standard curve in accordance with insulin dilution 
was obtained. 
When an affinity-purified polyclonal rabbit antibody was used in an ICT-EIA for assay of 
ferritin (450 kDa), 1 zmol (0.001 amol; 1  10-21 moles) of ferritin was detected [Hashida, 
1990]. The average number of -D-galactosidase labeled antibody Fab’ molecules bound per 
ferritin molecule was calculated to be 1.0-1.4. In addition, the detection limit of the ┚-D-
galactosidase activity was 1 zmol. On the other hand, the average number of bound 
enzyme-labeled antibody molecules per peptide molecule was calculated to be 0.001-0.01. 
Therefore, the peptide detection limit of this immunoassay was estimated to be between 0.1-
1 attomoles. Thus, it is likely that detection of 0.1 amol (0.02 µU) of a insulin will be possible 
if an affinity-purified antibody is used. 
As described in the “ Introduction “, blood samples have to be collected every 30 min for 2 h 
to assess the secretion of insulin in the OGTT. If the urinary insulin level reflects the serum 
insulin level, then the secretion of insulin after glucose ingestion may be easily assessed by 
measurement of urinary insulin levels. In the ICT-EIA of this study, the urinary insulin 
levels correlated well with the serum insulin levels at 1 h after glucose ingestion (Fig. 7). 
Thus, the level of insulin in urine appears to reflect the level in serum suggesting that 
measurement of insulin in urine may be useful for assessing insulin secretion. 
A comparison of the insulin levels in urine collected early in the morning from NDNO and 
NDO subjects and from DM patients showed that the levels were significantly higher in 
NDO subjects and in DM patients than in NDNO subjects (P < 0.01 and P < 0.001 
respectively) (Fig. 8). These results indicate that an increase in insulin levels may be a 
clinically important biomarker of obesity and diabetes risk. 
We previously developed a highly sensitive ELISA for urinary growth hormone (GH) 
[Hashida, 1987, Sukegawa, 1988], which showed that assay of GH during nocturia was 
useful as a supporting diagnostic index of the pituitary dwarf. We have also recently 
developed an ultra-sensitive ICT-EIA for urinary soluble human insulin receptor 
ectodomain (sIR) and found that urinary sIR levels correlated well with sIR blood levels 
[Umehara, 2009]. Furthermore, the levels of urinary sIR in DM patients were significantly 
higher than those in NDO subjects and DM patients. Therefore, urinary biomarkers can be 
useful for both physiological and clinical studies. 
In this study, urine samples with micro- and macro-albuminuria were excluded. Urinary 
insulin and resistin levels were expressed as ratios of urinary concentration to milligrams of 
urinary creatinine. Urinary insulin levels correlated well with urinary resistin levels (r = 
0.426, P < 0.01) (Fig. 10). Further studies with larger numbers of patients will be needed to 
determine the cut-off value and criteria for insulin as a diabetic risk biomarker. 
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Insulin and resistin levels in the urine of 42 DM patients were measured and are expressed relative to 
urinary creatinine (Cre). The regression equation and the calculated correlation coefficient (r = 0.426, P < 
0.01) are shown. 
Fig. 10. Correlation between urinary insulin and resistin levels. 
In summary, we have presented a new ultra-sensitive enzyme immunoassay for insulin, the 
ICT-EIA. This ICT-EIA can specifically measure insulin in urine, without any requirement 
for sample extraction or concentration. Urinary insulin and resistin levels were increased in 
patients with diabetes. ICT-EIA may be useful for both physiological and clinical studies of 
diabetic risk and urinary insulin may be used as a non-invasive maker that is relative to 
serum insulin. Therefore, measurement of urinary insulin levels will be useful in studies on 
dietary counseling and exercise guidance for patients with diabetes. 
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